Displaying drugs 2176 - 2200 of 2320 in total
Grape seed oil
Grape seed oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Grape seed oil is a plant/plant extract used in some OTC (over-the-counter) products. …
Taraxacum officinale leaf
Taraxacum officinale leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Taraxacum officinale leaf is a plant/plant extract used in some OTC (over-the-counter) products. …
TEL540-548
TEL540-548 is a recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase reverse transcriptase (hTERT).
Investigational
Matched Description: … TEL540-548 is a recombinant peptide consisting of the amino acid residues 540 to 548 of the human telomerase …
Benzimate
Benzimate is the lead compound selected from a series of compounds known as benzimidazoles. The anti-cancer and anti-viral activity of the benzimidazoles was originally investigated by the Proctor & Gamble Company beginning in the 1990's. It is currently under investigation by AmpliMed and is in phase I of clinical trial.
Investigational
Matched Description: … Benzimate is the lead compound selected from a series of compounds known as benzimidazoles. …
VP025
VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. VP025 may inhibit immune system activation and protect motoneurons from injury. It also shows the ability to reduce inflammation across the blood-brain barrier and improve correlates of memory and learning function. It is being developed to...
Investigational
Matched Description: … It is considered to be a systemic anti-inflammatory and neuroprotective agent. ... VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol ... developed to target the chronic inflammation within the central nervous system that is associated with a …
Veltuzumab
Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
Investigational
Matched Description: … Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials …
Prasinezumab
Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).
Investigational
Matched Description: … Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of …
Recombinant Super-Compound Interferon
Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.
Investigational
Matched Description: … Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified …
Itolizumab
Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
Investigational
Matched Description: … Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and …
PR006
PR006 is a non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene. It is being investigated for the treatment of dementia.
Investigational
Matched Description: … PR006 is a non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene …
CB-010
CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.
Investigational
Matched Description: … CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. …
MOD-5014
MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational
Matched Description: … MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. …
Diridavumab
Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
Investigational
Matched Description: … Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics …
Bixalomer
Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers).
Investigational
Matched Description: … Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 …
Orilanolimab
Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)).
Investigational
Matched Description: … Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects …
Imsidolimab
Imsidolimab is under investigation in clinical trial NCT03633396 (A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis).
Investigational
Matched Description: … Imsidolimab is under investigation in clinical trial NCT03633396 (A Study to Evaluate the Efficacy and …
Fasinumab
Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). It is currently under investigation for the treatment osteoarthritic pain and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e. NSAIDs and/or opioids) in this patient population. NGF was first discovered...
Investigational
Matched Description: … Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). …
BREN-02
BREN-02 is a recombinant human homeoprotein Engrailed 1 (rhEN1).
Investigational
Matched Description: … BREN-02 is a recombinant human homeoprotein Engrailed 1 (rhEN1). …
CALY-002
CALY-002 is a humanized monoclonal antibody targeting interleukin-15.
Investigational
Matched Description: … CALY-002 is a humanized monoclonal antibody targeting interleukin-15. …
Pidacmeran
Pidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
Investigational
Matched Description: … Pidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and …
Domagrozumab
Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).
Investigational
Matched Description: … Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety …
MBP-091
MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).
Investigational
Matched Description: … MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) …
Cellspan Esophageal Implant
The Cellspan Esophageal ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a polyurethane tubular mesh cell delivery device.
Investigational
Matched Description: … ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a …
PYM50018
PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in...
Investigational
Matched Description: … PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. ... When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle …
Plozalizumab
Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to...
Investigational
Matched Description: … Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found ... The recruitment of macrophages to the arterial wall is believed to be a critical step in the development …
Displaying drugs 2176 - 2200 of 2320 in total